Case report: an individual observation, not an estimate of how well the treatment works for other patients.

Who was studied?

One patient with HER2-positive, PD-L1-negative metastatic gastric adenocarcinoma.

What does the publication report?

A response after two cycles and progression-free survival of 6.5 months were reported.

Reading the original figures

Four dated columns of CT scans showing lesions at baseline, during response and at later progression in one patient.View full size ↗
A case followed across successive scans

Read each row across the four scan dates. The authors show early regression, including at nonirradiated sites, followed by later progression. The complete sequence matters: one favorable scan is not the whole disease course. This is a single gastric-cancer case treated with a PRaG-derived combination including RC48.

© 2024 Liu, Wang, Zhang, Lu and Yang · Frontiers in Immunology, 2024 · Figure 3 · CC BY 4.0. Reproduced without alteration.

Safety findings

The abstract does not provide a complete graded adverse-event profile.

How should we interpret it?

A single patient cannot establish efficacy or predict an individual outcome. Prior and concurrent treatments limit attribution.

Read the original source

This independently written summary was checked against the publicly available abstract. Selected figures, where included, are checked against the full publication. This is not a full-paper translation or a clinical recommendation.

Combination treatment with anti-HER2 therapeutic antibody RC48, PD-1 inhibitor, radiotherapy, and granulocyte macrophage-colony stimulating factor (GM-CSF) in patient with metastatic gastric cancer: a case report · DOI: 10.3389/fimmu.2024.1321946 · PMID: 38361930

Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.